FDA approves dupilumab for severe eczema
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Drug Discovery"
DOI: 10.1038/nrd.2017.90
Abstract: The new contender seems to offer a lower risk of depression, somnolence and akathisia than the established competition. It still carries a black box warning, however, citing the risk of depression and suicidality. Teva, which… read more here.
Keywords: fda approves; drug; dupilumab severe; approves dupilumab ... See more keywords